Skip to main content
May 21, 2022
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Olympia A Clinical Trial
Breast Cancer Treatment
PARP Inhibitors improve outcomes in BRCA mutated breast cancer. FDA approves Lynparza for treatment of TNBC and early stage breast cancer.
By Dr. C.H. Weaver M.D.
Apr 30, 2022
CLOSE
CLOSE
CLOSE
CLOSE